Compare SOLAI Limited (SLAI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs Twist Bioscience Corp — how do they compare? SOLAI Limited trades at $3.72 (market cap $880.09M), while Twist Bioscience Corp trades at $159.89 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 11.5× SOLAI Limited's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SOLAI Limited for 40 Days and Twist Bioscience Corp for 27 Days on average.
| SLAI | TWST | |
|---|---|---|
Market Cap | $880.09M | $10.08B |
Volume | 122,720 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $21.63 | $205.00 |
52-Week Low | $2.74 | $25.45 |
Typical Hold Time | 40 Days | 27 Days |
Enterprise Value | $879.73M | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement. The technical picture is bullish based on moving averages and oscillators, though the stock faces delisting proceedings from the NYSE. Fundamentally, the company shows severe distress with negative gross and net income margins, high revenue decline, and substantial losses despite a low P/B ratio. Recent news highlights governance changes amid exchange compliance issues.
The outlook is highly risky due to financial instability and delisting threat. Investment opportunity exists only for speculative traders betting on a turnaround, given the low valuation multiple. Key risks include continued cash burn, inability to achieve profitability, and loss of major exchange listing impacting liquidity and investor confidence.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
